Faron Pharmaceuticals Oy
(LSE:FARN)
£
0.40
-0.014 (-3.41%)
Market Cap: 80.34 Mil
Enterprise Value: 90.91 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 22/100 
Half Year 2025 Faron Pharmaceuticals Oy Earnings Call Transcript
Aug 27, 2025 / 01:00PM GMT
Release Date Price:
£1.95
(-4.49%)
Key Points
Positve
- Faron Pharmaceuticals Oy (FRA:4FR) reported a significant increase in complete remission rates from 28% to 43% in their BEXMAB trial for high-risk myelodysplastic syndrome (MDS), marking one of the highest rates ever reported for this patient group.
- The company received positive feedback from the FDA, supporting a seamless Phase 2/3 trial design with potential for accelerated approval based on interim efficacy and overall survival data.
- Faron Pharmaceuticals Oy's financial position remains strong, with a cash balance of $13.5 million and additional undrawn tranches from a convertible loan facility.
- The company has expanded its oncology pipeline, including trials for solid tumors and sarcomas, with promising combinations of BEX with standard care treatments.
- Faron Pharmaceuticals Oy has strengthened its intellectual property position with a patent extension up to 2040, providing broader protection for treating CLEVER-1 positive cancers with BEX.
Negative
- Despite positive trial results, the company faces challenges in navigating complex partnering discussions to balance de-risking development plans while maintaining shareholder value.
- The timeline for potential accelerated approval is projected for 2028, indicating a lengthy path to market for their lead product.
- Faron Pharmaceuticals Oy's net asset position is negative, at minus $16.7 million, reflecting ongoing financial challenges despite a strong cash balance.
- The company must address the FDA's request to explore lower dosing levels in their trials, which could complicate the development process.
- There is uncertainty regarding the EMA's acceptance of the new 2023 criteria for endpoint evaluation, which could impact the trial's success in Europe.
Julia Balanova Faron Pharmaceuticals Oy;Vice President
Investor Relations
Welcome to the half year report conference call for Faron Pharmaceuticals. Very excited to have you all on the call. We know there are quite a few of you still joining. But we are excited to talk to you about the significant clinical and financial milestones that have been achieved in the first half of 2025 for Faron. We've got our corporate disclaimer, as we always do, included for your review.
And then we've got our agenda. We have three presenters today. We have Dr. Juho Jalkanen, the CEO.
Juho Jalkanen
Faron Pharmaceuticals Oy - Chief Executive Officer
Hello, everyone.
Julia Balanova Faron Pharmaceuticals Oy;Vice President
Investor Relations
We have a Head of Clinical and Regulatory, Dr. Petri Bono.
Petri Bono Faron Pharmaceuticals Oy;Chief Medical Officer;Julia Balanova Faron Pharmaceuticals Oy
Hello, everybody.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers